SCHEMBL6315249

SCHEMBL6315249

Nc1onc(-c2ccccn2)c1C(=O)NC(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
EGLN1 Q9GZT9 1/20 0.40
TACR3 P29371 1/20 0.40
LMNA P02545 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
S1PR3 Q99500 3/20 0.39
S1PR2 O95136 1/20 0.39
S1PR4 O95977 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
SLC2A1 P11166 1/20 0.38
GABRA5 P31644 1/20 0.38
HPGDS O60760 2/20 0.38
PRCP P42785 2/20 0.38
S1PR1 P21453 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317594 0.82 CA1 (0.48) ALDH1A1TACR3LMNACA1CA2
SCHEMBL6316151 0.81 CA1 (0.56) LMNACA1CA2CA4CA7
SCHEMBL6315950 0.81 KDM4E (0.43) ALDH1A1LMNACA1CA2CA4
SCHEMBL6316669 0.81 ALDH1A1 (0.44) ALDH1A1TACR3LMNACA1CA2
SCHEMBL6317061 0.81 ALDH1A1 (0.44) ALDH1A1TACR3CA1CA2CA4
SCHEMBL6316689 0.79 ALDH1A1 (0.47) ALDH1A1TACR3LMNACA1CA2
SCHEMBL6321635 0.79 ALDH1A1 (0.47) ALDH1A1CA1CA2CA4CA7
SCHEMBL6319053 0.79 HPGDS (0.54) ALDH1A1EGLN1LMNAKMT2AMEN1
SCHEMBL6318141 0.78 RET (0.47) LMNAKMT2AMEN1GABRA5L3MBTL1
SCHEMBL6316676 0.78 MEN1 (0.47) ALDH1A1TACR3LMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ALDH1A1 4444/4885EGLN1 4030/4885TACR3 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.